title: Effect of trimetazidine on the nucleotide profile in rat kidney with ischemia-reperfusion injury.
abstract: Ischemia-reperfusion injury is often responsible for delayed graft function after transplantation. Trimetazidine (TMZ) is an antioxidant agent used to protect grafts from ischemia-reperfusion injury. The aim of the study was to examine the effect of TMZ on nucleotide profile in rat kidney with ischemia-reperfusion injury. The study was carried out on Wistar rats divided into two groups: animals treated with TMZ and control group receiving placebo. TMZ 10mg/kg/day was administrated for 30 days. Concentrations of adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), adenosine (Ado), guanosine triphosphate (GTP), guanosine diphosphate (GDP), guanosine monophosphate (GMP), guanosine (Guo), inosine monophosphate (IMP), inosine (Ino), hypoxanthine (Hyp), xanthine (Xan), uric acid (UA), uridine (Urd), nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) were determined in kidney tissues after ischemia-reperfusion using HPLC. The total adenine nucleotide concentration (TAN) and adenylate energy charge (AEC) were also determined. Moreover the kidneys were evaluated histologically. Tissue concentrations of ATP, ADP, AMP, TAN and AEC were significantly increased in kidneys from rats treated with TMZ in comparison with rats receiving placebo. Concentrations of products of nucleotide degradation: inosine (Ino), guanosine (Guo) and uridine (Urd), as well as oxypurines: Hyp and Xan, were significantly decreased in rats treated with trimetazidine. Moreover, significantly less pronounced acute tubular necrosis was observed in kidneys of rats treated with TMZ. These results suggest that trimetazidine protects against dephosphorylation of nucleotides and ischemic damage.
authors.affiliation: Department of Nephrology, Transplantology and Internal Medicine of Pomeranian Medical University, Szczecin, Powstańców Wlkp 72, 70-111 Szczecin, Poland. domanle@sci.pam.szczecin.pl
authors.forename: Leszek
authors.initials: L
authors.lastname: Domanski
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Sulikowski
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Safranow
authors.forename: Andrzej
authors.initials: A
authors.lastname: Pawlik
authors.forename: Maria
authors.initials: M
authors.lastname: Olszewska
authors.forename: Dariusz
authors.initials: D
authors.lastname: Chlubek
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Urasinska
authors.forename: Kazimierz
authors.initials: K
authors.lastname: Ciechanowski
mesh_terms: D000227:Adenine Nucleotides / Q000378:metabolism*; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D004195:Disease Models, Animal; D006084:Graft Rejection / Q000517:prevention & control; D007673:Kidney Cortex Necrosis / Q000517:prevention & control; D007674:Kidney Diseases / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D007684:Kidney Tubules / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D009926:Organ Preservation; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D014292:Trimetazidine / Q000494:pharmacology*
chemical_list: D000227:Adenine Nucleotides; D000975:Antioxidants; D014292:Trimetazidine